Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference

May 16, 2024

https://www.globenewswire.com/news-release/2024/05/16/2883857/28255/en/Evoke-Pharma-to-Present-Additional-GIMOTI-Healthcare-Utilization-Data-Focused-on-Gastroparesis-Care-Insights-in-Women-at-2024-Digestive-Disease-Week-DDW-Conference.html

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.